-
Mashup Score: 1
During a Targeted Oncology™ Case-Based Roundtable™ event, Robert J. Motzer, MD, examined the impact of the CheckMate 214 and CheckMate 9ER trials of nivolumab/ipilimumab and nivolumab/cabozantinib in patients with advanced renal cell carcinoma. This is the first of 2 articles based on this event.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3Next Steps in Study of PPAR-α Inhibitor Plus Nivolumab in RCC - 2 month(s) ago
Bruno R. Bastos, MD, discusses the future following a study assessing the changes among patients with renal cell carcinoma who were treated with nivolumab and TPST-1120.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 163Integrative Analyses of Tumor and Peripheral Biomarkers in the Treatment of Advanced Renal Cell Carcinoma - 2 month(s) ago
AbstractThe phase III JAVELIN Renal 101 trial demonstrated prolonged progression-free survival (PFS) in patients (N = 886) with advanced renal cell carcinoma treated with first-line avelumab + axitinib (A+Ax) versus sunitinib. We report novel findings from integrated analyses of longitudinal blood samples and baseline tumor tissue. PFS was associated with elevated lymphocyte levels in the sunitinib arm and an abundance of innate immune subsets in the A+Ax arm. Treatment with A+Ax led to greater T-cell repertoire modulation and less change in T-cell numbers versus sunitinib. In the A+Ax arm, patients with tumors harboring mutations in ≥2 of 10 previously identified PFS-associated genes (double mutants) had distinct circulating and tumor-infiltrating immunologic profiles versus those with wild-type or single-mutant tumors, suggesting a role for non–T-cell–mediated and non–natural killer cell–mediated mechanisms in double-mutant tumors. We provide evidence for different immunomodulatory m
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Study Links Prior Thymectomy to Higher Rate of Nephrectomy in RCC - 3 month(s) ago
Regina Barragan-Carrillo, MD, discusses findings from a large population-based study which found there to be significantly higher rates of nephrectomy among patients with renal cell carcinoma who had received prior thymectomy vs the incidence of nephrectomy overall.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 9PPAR-α Inhibitor Plus Nivolumab Shows Promise in RCC - 3 month(s) ago
Bruno R. Bastos, MD, discusses findings from a study which assessed the pharmacodynamic and radiographic changes among patients with renal cell carcinoma who were treated with the combination of nivolumab and TPST-1120.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 5
Kidney cancer is the seventh leading cause of cancer in the world, and its incidence is on the rise. Renal cell carcinoma (RCC) is the most common form and is a heterogeneous disease comprising three major subtypes that vary in their histology, clinical course and driver mutations. These subtypes include clear cell RCC, papillary RCC and chromophobe RCC. Molecular analyses of hereditary and…
Source: www.nature.comCategories: General Medicine News, NephrologyTweet
-
Mashup Score: 38Is Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma a Disease-Modifying Therapy? - 4 month(s) ago
Retrospective and prospective studies have shown that SABR can be safely combined with immunotherapy, delay initiation of systemic therapy, and control progressing lesions without changing systemic therapy in patients with oligometastatic RCC. Larger randomized trials are needed to consolidate the role of SABR in this space.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 7Deciphering Immunotherapy Responses in Advanced RCC: A Deep Dive into the HCRN Study - Nourhan El Ahmar - 6 month(s) ago
Pedro Barata interviews Nourhan El Ahmar to discuss the significant work conducted by El Ahmar’s team. The work focused on a subgroup analysis of the HCRN GU16-260 platform study that investigated the use of nivolumab with ipilimumab as salvage therapy for patients with advanced renal cell carcinoma. El Ahmar delves into the specifics of the trial, explaining how their lab played a crucial role…
Source: www.urotoday.comCategories: General Medicine News, UrologyTweet-
Deciphering immunotherapy responses in advanced #RCC: a deep dive into the HCRN study. Join @Nourhanelahmar @BrighamWomens and @PBarataMD @caseccc in discussing a subgroup analysis of the HCRN GU16-260 platform study, of nivo and ipi as salvage therapy > https://t.co/ky92Q1YAsu https://t.co/NIRu98LQ5N
-
-
Mashup Score: 6Tumor Board Tuesday 2023 Conversations - 7 month(s) ago
Tumor Board Tuesdays is a regularly scheduled, Twitter-based case discussion forum led by expert faculty exploring cases in various solid tumor malignancies. The series will focus on practice application in the clinic. Experts will present recent data and focus on realistic case examples. The advantage to this format is the ability to comment and receive feedback from the experts.
Source: integrityce.comCategories: Latest Headlines, Oncologists2Tweet
-
Mashup Score: 0Dovitinib Companion Diagnostic Shows Results in RCC - 7 month(s) ago
The tool shows promise to predict a patient’s response to dovitinib to better inform treatment options for patients with renal cell carcinoma and other solid tumors.
Source: www.targetedonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
Robert J. Motzer, MD, evaluated the CheckMate 214 and CheckMate 9ER trials of nivolumab/ipilimumab & nivolumab/cabozantinib in patients with advanced #RCC. @motzermd @MSKCancerCenter https://t.co/Prd5gBK35Q